Feature Stock
Join the SmallCapReview mailing list
 

   
   
   
   
   

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

  

OraSure Technologies (OSUR)

Website: www.OraSure.com

"Received a unanimous positive recommendation for the Company's OraQuick(R) In-Home HIV Test from the U.S. Food and Drug Administration (FDA) Blood Products Advisory Committee."

Overview

OraSure (OSUR) is a leader in the development, manufacture and distribution of oral fluid diagnostic and collection devices and other technologies designed to detect or diagnose critical medical conditions. 

Its innovative products include rapid tests for the detection of antibodies to HIV and HCV at the point of care and testing solutions for detecting various drugs of abuse. In addition, the Company is a leading provider of oral fluid sample collection, stabilization and preparation products for molecular diagnostic applications. 

OraSure's portfolio of products is sold globally to various clinical laboratories, hospitals, clinics, community-based organizations and other public health organizations, research and academic institutions, distributors, government agencies, physicians' offices, and commercial and industrial entities. The Company's products enable healthcare providers to deliver critical information to patients, empowering them to make decisions to improve and protect their health.

OSUR Investor Highlights

  • Announced that the U.S. Food and Drug Administration (FDA) Blood Products Advisory Committee provided a unanimous positive recommendation for the Company's OraQuick(R) In-Home HIV Test.

  • Consolidated revenues were $20.9 million for the first quarter of 2012, a 20% increase from the comparable quarter of 2011.

  • Cash totaled $22.8 million at March 31, 2012.

  • According to the Centers for Disease Control and Prevention, despite current testing options, there are approximately 1.2 million people in the U.S. that have HIV and approximately 240,000 of them are unaware of their status.

  • The OraQuick ADVANCE(R) test is the first and only FDA-approved and CLIA-waived rapid point-of-care test that can detect antibodies to both HIV-1 and HIV-2 in oral fluid in 20 minutes.

Recent News and Press Releases

OraQuick(R) In-Home HIV Test Receives Unanimous Positive Recommendation From FDA Advisory Committee

OraSure Announces 2012 First Quarter Financial Results

For the latest Quote and News on OSUR Click Here.

Three Month Chart

Management

Douglas A. Michels - President and Chief Executive Officer

Douglas A. Michels joined OraSure Technologies, Inc. in June 2004, as President and Chief Executive Officer and as a member of the Board of Directors. He is an Executive Officer and member of the Executive Committee.

Prior to joining the Company, Mr. Michels spent 19 years with Johnson & Johnson and seven years with Abbott Laboratories. At Johnson & Johnson, he was President, International, for Ortho-Clinical Diagnostics, Inc., and President of Johnson & Johnson Health Care Systems, Inc. He also held numerous General Management and Marketing and Sales positions, in both medical devices and diagnostics. While at Abbott Laboratories, he held various sales and marketing positions.

Mr. Michels currently serves as a member of the U.S. Presidential Advisory Council on HIV/AIDS (PACHA) and serves on the Board of St. Luke's Hospital and Health Network in Bethlehem, PA and West Pharmaceutical Services, Inc, in Lionville, PA. Mr. Michels previously served on the Board of the National Blood Foundation, the Board of the National Committee for Quality Health Care, and the Coalition to Protect America's Health Care.

Mr. Michels received a B.S. degree in Public Health Administration from the University of Illinois in 1978 and an MBA from Rutgers University in 1990.

Ronald H. Spair - Chief Operating officer and Chief Financial Officer

Ronald H. Spair joined the Company in November 2001, as Executive Vice President and Chief Financial Officer and was promoted to Chief Operating Officer and Chief Financial Officer at which time he also became a member of the Board of Directors in October 2006. He is an Executive Officer and member of the Executive Committee.

Mr. Spair has extensive senior financial experience in the pharmaceutical and biotechnology industries to OraSure Technologies. Before joining OraSure he was with Delsys Pharmaceutical Corporation as Vice President and Chief Financial Officer. Prior to Delsys, he was Chief Financial Officer for three public companies – Supergen, Inc., Sparta Pharmaceuticals, Inc., and Envirogen, Inc. During this period, Mr. Spair had responsibility for directing finance, accounting, financial planning, treasury, human resources, risk management and information technology matters at these companies. Mr. Spair has also had extensive experience negotiating mergers and acquisitions, development and licensing transactions and corporate financings.

Mr. Spair is a Certified Public Accountant and received both his B.S. in Accounting and his MBA from Rider College.

Stephen R. Lee - Executivwe Vice President and Chief Science Officer

Stephen R. Lee, Ph.D. joined the Company in September 2005, as Executive Vice President and Chief Science Officer. He is an Executive Officer of the Company.

Dr. Lee has more than 25 years of experience in the immunodiagnostic industry and joined OraSure from Ortho-Clinical Diagnostics, a Johnson & Johnson company. While at Ortho-Clinical Diagnostics, Dr. Lee served as Vice President, Assay Research & Development, Executive Director, Worldwide Immunodiagnostic Product Development and Director, Infectious Disease Assay Development. Dr. Lee has had responsibility for or direct involvement in, the development of over 40 major diagnostic assays, in such areas as infectious disease, cardiology, oncology and other conditions.

In 1997, Dr. Lee was awarded The Johnson Medal, Johnson & Johnson's highest award for Research and Development. Prior to joining Ortho-Clinical Diagnostics, Dr. Lee worked as a scientist for both Wampole Labs and Immunicon Corporation.

Dr. Lee received his Ph.D. degree in Biochemistry from Cardiff University (UK) and his BSc. in Biochemistry from Sheffield University (UK).

SEC Filings

OSUR filings with the SEC can be found here.

Contacts

OraSure Technologies

220 East First Street
Bethlehem, PA 18015-1360
Phone: 610-882-1820
Fax: 610-882-1830

SmallCapReview.com feature stock reports are intended to be stock ideas, not recommendations. Please do your own research before investing. It is crucial that you at least look at current SEC filings and read the latest press releases. Information contained in this report was extracted from current documents filed with the SEC, the company website and other publicly available sources deemed reliable. For more information see our disclaimer section, a link of which can be found on our website. This document contains forward-looking statements, particularly as related to the business plans of the Company, within the meaning of Section 27A of the Securities Act of 1933 and Sections 21E of the Securities Exchange Act of 1934, and is subject to the safe harbor created by these sections. Actual results may differ materially from the Company's expectations and estimates. The information provided in this report is not intended for distribution to, or use by, any person or entity in any jurisdiction or country where such distribution or use would be contrary to law or regulation or which would subject us to any registration requirement within such jurisdiction or country.

Copyright SmallCapReview. All rights reserved. SCR is not a Registered Broker/Dealer or Financial Advisor. All materials presented on our website and individual reports released to the public through this website, e-mail or any other means of transmission are not to be regarded as investment advice and are only for informative purposes. Before making a purchase or sale of any securities featured on our web site or mentioned in our reports, we strongly encourage and recommend consultation with a registered securities representative. This is not to be construed as a solicitation or recommendation to buy or sell securities. As with any stock, companies we select to profile involve a degree of investment risk and volatility, particularly small-caps. All investors are cautioned that they may lose all or a portion of their investment if they decide to make a purchase in any of our profiled companies. Past performance of our profiled stocks is not indicative of future results. The profile and opinions expressed herein are expressed as of the date the profile is posted on site and are subject to change without notice. No investor should assume that reliance on the views, opinions or recommendations contained herein will produce profitable results. SmallCapReview may hold positions in securities mentioned herein, and may make purchases or sales in such securities featured on our website or within our reports  In order to be in full compliance with the Securities Act of 1933, Section 17(b), SCR will disclose in it's disclaimer, what, if any compensation was received for our efforts in researching, presenting and disseminating this information to our subscriber database and featuring the report on the SmallCapReview website. SmallCapReview has not been compensated for its efforts with regards to OraSure Technologies.

We encourage our readers to invest carefully and read the investor information available at the web sites of the Securities and Exchange Commission (SEC) at: http://www.sec.gov and/or the National Association of Securities Dealers (NASD) at: http://www.nasd.com . Readers can review all public filings by companies at the SEC's EDGAR page. The NASD has published information on how to invest carefully at its website.